Imugene Limited (ASX: IMU) managing director and CEO Leslie Chong chats with Andrew Scott from Proactive about the announcement of a partnership with contract development and manufacturing organisation ABL to advance IMU’s oncolytic virus candidate towards later-phase clinical trials. Chong discusses last month's capital raise of $80 million and three presentations Imugene will be giving in November at the Society for Immunotherapy of Cancer.
Imugene talks ABL partnership for VAXINIA and $80 million institutional capital raise
